Zydus Lifesciences (BOM:532321) ROCE %: 19.43% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:532321 Zydus Lifesciences Ltd BOM:532321
93 GF Score
Price ₹1,142.75
GF Value ₹1,155.81
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Zydus Lifesciences ROCE %?

Zydus Lifesciences BOM:532321 -0.93% 93 ROCE % is 19.43% as of Mar. 2026. GuruFocus rates BOM:532321 with a GF Score™ of 93/100 and a GF Value™ of ₹1,155.81 (Fairly Valued). The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Zydus Lifesciences's annualized ROCE % for the quarter that ended in Mar. 2026 was 19.43%.

Zydus Lifesciences  (BOM:532321) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Zydus Lifesciences ROCE % Related Terms

Zydus Lifesciences ROCE % Historical Data

* Premium members only.

The historical data trend for Zydus Lifesciences's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zydus Lifesciences ROCE % Chart

Zydus Lifesciences Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.41 13.51 21.98 23.49 21.54

Zydus Lifesciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.84 28.48 19.11 15.84 19.43
BOM:532321
93GF Score
Zydus Lifesciences Ltd BOM:532321
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zydus Lifesciences ROCE % Calculation

Zydus Lifesciences's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=69861/( ( (372017 - 90416) + (524066 - 157119) )/ 2 )
=69861/( (281601+366947)/ 2 )
=69861/324274
=21.54 %

Zydus Lifesciences's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=71308/( ( (0 - 0) + (524066 - 157119) )/ 1 )
=71308/( ( 0 + 366947 )/ 1 )
=71308/366947
=19.43 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 19.43% mean?
Zydus Lifesciences (BOM:532321) has a ROCE % of 19.43% as of Mar. 2026.
Is Zydus Lifesciences' ROCE % too high?
Zydus Lifesciences' current ROCE % is 19.43%. The Drug Manufacturers industry median ROCE % is 7.05. Zydus Lifesciences' value of 19.43% is 175.6% above this industry median. Overall, Zydus Lifesciences has a GF Score™ of 93/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Zydus Lifesciences' ROCE % compare to ZTS and UTHR?
Zydus Lifesciences' ROCE % of 19.43% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.05. Zydus Lifesciences' value of 19.43% is 175.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.05, based on 963 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zydus Lifesciences's current ROCE % of 19.43% is 175.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zydus Lifesciences's current ROCE % is 19.43%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zydus Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Zydus Lifesciences (BOM:532321) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,155.81, compared to a current price of ₹1,142.75 — trading 1.1% below its estimated fair value. The current ROCE % is 19.43% and 175.6% above the Drug Manufacturers industry median of 7.05. Zydus Lifesciences' overall GF Score™ is 93/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Zydus Lifesciences (BOM:532321), the current ROCE % is 19.43% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zydus Lifesciences (BOM:532321) Overvalued in 2026?

Based on GuruFocus' analysis, Zydus Lifesciences stock appears to be undervalued. The current stock price of ₹1,142.75 is trading 1.1% below its estimated GF Value™ of ₹1,155.81. GuruFocus considers Zydus Lifesciences to be Fairly Valued.

Key valuation signals for BOM:532321:

  • ROCE %: 19.43%
  • GF Value™: ₹1,155.81 vs. price of ₹1,142.75 (1.1% below fair value)
  • GF Score™: 93/100 with 5 warning signs
  • Industry Position: 175.6% above the Drug Manufacturers median

No single metric tells the full story. See the BOM:532321 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zydus Lifesciences Business Description

Other Exchanges ZYDUSLIFE:India
Address Scheme No. 63, Sarkhej-Gandhinagar Highway, Zydus Corporate Park, Survey No. 536, Near Vaishnodevi Circle, Khoraj (Gandhinagar), Ahmedabad, GJ, IND, 382481
Zydus Lifesciences Ltd is a specialty and generic drug manufacturing company. It is engaged in the research, development, production, marketing, and distribution of pharmaceutical products. The product portfolio of the company includes Active Pharmaceutical Ingredients (API), human formulations, animal health and veterinary, and consumer health and wellness products. Its products are marketed under brands like Amlodac, Inditel, Pivasta, and others. The company's operating segments are: Pharmaceuticals, which derives key revenue, and Consumer products. Geographically, it generates maximum revenue from the United States, followed by India, and other countries.
93GF Score

Get the complete analysis for BOM:532321

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,142.75
Price
₹1,155.81
GF Value